药易购(300937) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥1,010,149,855.81, representing a year-over-year increase of 0.26%[3] - Net profit attributable to shareholders decreased by 46.63% year-over-year to ¥1,835,713.94, while the net profit after deducting non-recurring gains and losses fell by 69.25% to ¥884,089.15[3] - The total operating revenue for the third quarter was CNY 3,235,469,610.27, a slight increase from CNY 3,212,357,594.74 in the previous year, representing a growth of approximately 0.72%[15] - The net profit for Q3 2024 was CNY 10,473,171.26, a decrease from CNY 49,645,720.30 in Q3 2023, representing a decline of approximately 78.9%[16] - The total operating profit for Q3 2024 was CNY 10,234,621.40, down from CNY 60,045,240.85 in the same period last year, indicating a decrease of about 83.0%[16] - The total comprehensive income attributable to the parent company's owners for Q3 2024 was CNY 13,931,460.39, compared to CNY 51,654,269.26 in the same period last year, a decrease of about 73.0%[17] Cash Flow - The operating cash flow for the year-to-date period increased significantly by 129.74% to ¥38,318,291.45[3] - Net cash flow from operating activities improved by 129.74% to ¥38,318,291.45, driven by accelerated customer payments and improved inventory turnover[9] - The cash flow from operating activities for the current period was CNY 2,431,301,554.79, down from CNY 3,107,444,951.09 in the previous year, indicating a decrease of approximately 21.8%[18] - The net cash flow from operating activities for Q3 2024 was 38,318,291.45 CNY, a significant improvement compared to -128,853,482.60 CNY in Q3 2023[19] - The company reported a total cash outflow from operating activities of 2,436,079,170.57 CNY, down from 3,391,258,205.22 CNY in the previous year[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,694,786,201.77, reflecting a 0.46% increase from the previous year[3] - Total liabilities rose to CNY 849,058,831.78 from CNY 831,023,467.80, indicating an increase of approximately 2.7%[15] - The company's non-current assets totaled CNY 318,687,922.33, up from CNY 310,622,601.68, reflecting a growth of about 2.2%[14] Shareholder Information - The total number of common shareholders at the end of the reporting period was 12,860[10] - The largest shareholder, Li Yanfei, holds 36.97% of shares, totaling 35,370,000 shares[11] - The total number of restricted shares at the beginning of the period was 54,371,875, with 21,353,065 shares released during the period[12] Expenses - The company's weighted average return on equity decreased to 0.22%, down by 0.23% compared to the previous year[3] - Financial expenses increased by 84.33% to ¥6,578,010.67 due to higher interest costs from increased borrowings[8] - Other income decreased by 55.81% to ¥1,391,409.14 primarily due to reduced government subsidies[8] - Research and development expenses for Q3 2024 were CNY 12,565,314.67, a slight decrease from CNY 14,122,063.35 in Q3 2023, reflecting a reduction of approximately 11.0%[16] - Sales expenses increased to CNY 180,912,080.87 in Q3 2024, compared to CNY 143,155,370.65 in Q3 2023, marking an increase of about 26.4%[16] Investment Activities - The company reported a net loss from investments of CNY 468,072.44 in Q3 2024, contrasting with a profit of CNY 403,817.23 in Q3 2023[16] - Cash flow from investing activities worsened by 99.79% to -¥24,940,175.33 due to increased investments in principal-protected financial products[9] - Total cash inflow from investing activities was 13,105,813.91 CNY, down from 16,220,277.06 CNY in the previous year[19] Government Subsidies - The company recognized a government subsidy of ¥191,540.64 during the reporting period, contributing to its non-recurring gains[4]